Venous Stents Market
Global Industry Analysis and Forecast 2023-2030
Market Value (2022)
USD 1,296.2 Million
Forecasted Value (2030)
USD 2,809.7 Million
CAGR (2023 - 2030)
Fastest Growing Region (2023 - 2030)
Iliac Vein Stent Technology, Wallstent Technology
Acute DVT, Chronic DVT/PTS, NIVL/MTS, Others
Leg, Chest, Abdomen, Others
The global Venous Stents Market was valued at USD 1,296.2 million in 2022 and is projected to reach USD 2,809.7 million by 2030, growing at a CAGR of 10.40% from 2023 to 2030.
The growing trend of outpatient procedures and daycare surgeries has also boosted the demand for venous stents. The aging population, prevalence of obesity, and sedentary lifestyles contribute to venous insufficiency, which can lead to conditions such as deep vein thrombosis, chronic venous insufficiency, and venous leg ulcers. Venous stents offer a minimally invasive treatment that reduces symptoms and improves the quality of life of patients suffering from these diseases. However, the high cost of venous stents and the lack of skilled healthcare professionals may hamper the market growth to some extent.
Analyst’s Review on Venous Stents Market
The development of several effective techniques for the precise placement of veins and increasing investments by key players in the development of flexible venous stents are likely to aid market growth. In addition, advances in stent technology and materials have made the procedure safer and more effective, thereby increasing the use of vein stenting. The development of bio-absorbable stents and the increasing adoption of drug-eluting stents are expected to create new opportunities for the venous stents market in the future.
Venous stents (VS) are used to treat central and peripheral venous stenosis. These stenoses can be caused by venous damage, inflammation, turbulent flow, and uremia. Venous stenoses are particularly problematic when associated with hemodialysis access for a patient with end-stage renal disease. These stents can be used in the legs, chest, or abdomen to treat conditions that block blood flow or cause chronic blood clots. Venous stenting is used as adjunctive therapy in patients with acute iliofemoral deep vein disease when there is residual venous occlusion (RVOO) after thrombolysis and balloon angioplasty, with the aim of restoring vascular patency and preventing PTS. They are implanted into a vein that is narrowed or blocked and act as scaffolds that keep the vein open and improve blood flow. Venous stenting is a minimally invasive procedure that has become an increasingly popular treatment option for conditions such as deep vein thrombosis, chronic venous insufficiency, and venous leg ulcers. Improvements in stent technology and materials have made the procedure safer and more effective.
Deep vein disease usually affects the venous system of the lower extremities, so thrombus formation begins in the deep vein of the calf and spreads nearby. It is a common venous thromboembolism (VTE) disease with an incidence of 1.6 in 1,000 per year. Deep vein thrombosis (DVT) is a blood clot that occurs in deep veins, most commonly in the legs but occasionally in the arms, mesenteric, and cerebral veins. It is classified as a venous thromboembolic illness and is the third most significant cause of death from cardiovascular disease, adhering to heart attack and stroke. Deep vein thrombosis is a dangerous medical condition that accounts for the majority of pulmonary embolism cases. It is used in individuals with post-thrombotic syndrome (PTS) following a prior deep vein thrombosis (DVT) to alleviate feelings of chronic pain and swelling and, in severe circumstances, to improve wound healing. Intravenous stenting is associated with a low risk of morbidity and mortality, and although significant advances have particularly improved stent design for use in the venous circulation which drives the venous stents market growth.
Vein stenting is a valuable treatment option for venous disease. Studies have shown that vein stenting provides favorable results in deep vein thrombosis, chronic venous insufficiency, and varicose veins. However, the high cost of venous stenting procedures has been a concern, especially compared to other treatment options viz., compression therapy and lifestyle interventions. Although vein stenting is an effective treatment option for venous diseases, such as deep vein thrombosis and chronic venous insufficiency, the cost of the procedure can be higher than other treatment options like compression therapy. Efforts are being made to improve the cost-effectiveness of venous stenting, including the development of innovative technologies and approaches.
The global venous stents market is segmented based on technology, disease, application, and geography.
Based on technology, the market is classified into Iliac vein stent technology and wallstent technology. Illiac vein stent technology registered a dominating market share of 75.9% in 2022 and is expected to expand significantly during the review period as a result of its increasing popularity, which may be attributed to its flexibility, MRI compatibility, high radial force, and low cost.
Based on disease, the venous stents market is segmented into acute DVT, chronic DVT/PTS, NIVL/MTS, and others. The acute DVT segment is slated to grow rapidly with a CAGR of 11.3% through 2030. Technological advancements in the treatment methods, as well as an increase in the number of people suffering from DVT, are likely to foster the segmental outlook.
Based on application, the venous stents market is categorized into leg, chest, abdomen, and others. The leg segment has attained a dominating position with a valuation of USD 551 million in 2022. The segment growth is accelerated by the increasing prevalence of deep vein thrombosis which has proliferated the need for venous stents.
Based on regional analysis, the global venous stents market is classified into North America, Europe, Asia Pacific, MEA, and Latin America.
Europe is dominating the global venous stents market and is forecast to depict a CAGR of 9.3% over the analysis timeline. In Europe, the venous stents market is speculated to continue to grow due to the increasing prevalence of venous diseases. Self-expanding stents, bioresorbable stents, coatings, and drug-eluting stents have all improved the safety and efficacy of venous stenting in Europe. Researchers at Oxford University, Imperial College, and the University of Sheffield collaborated with the tech company ThinkSono to train a machine learning AI algorithm (AutoDVT) that could distinguish DVT patients from those who were not diagnosed with DVT. These advancements are set to contribute to the market growth over the forecast period. In addition, the number of minimally invasive venous procedures performed for complex venous diseases has increased significantly in recent years, which has further fueled the growth of the venous stents market.
North America is the second leading region in the venous stents industry with a valuation of USD 423.2 million in 2022. The regional market growth is driven by the high prevalence of venous disease, particularly among the aging population, which has propelled product uptake in North America. Several studies have shown that venous stenting provides favorable results in deep vein thrombosis, chronic venous insufficiency, and varicose veins. In North America, the venous stents market share is expected to continue to grow due to the prevalence of venous diseases, and advances in stent technology have also played a prominent role in the widespread adoption of venous stents in North America. Self-expandable stents, bioresorbable stents, coatings, and drug-eluting stents have all improved the safety and effectiveness of venous stenting in North America. These advancements are also supplementing the overall growth of the venous stents market.
The global venous stents industry study report will provide valuable insights with an emphasis on the fragmented nature of the global market. Prominent players are focusing on several key business strategies, such as partnerships, mergers & acquisitions, product innovations, and joint ventures to expand their product portfolio and increase their respective market shares across different regions. Expansion & investments involve a range of strategic initiatives including investments in R&D activities, new manufacturing facilities, and supply chain optimization. The major players in the market are:
- Abbott Laboratories
- Becton, Dickinson and Company
- Boston Scientific Corporation
- Cardinal Health
- Cook Group Incorporated
- Koninklijke Philips N.V.
- Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd.
- L. Gore & Associates, Inc.
- May 2023 (Acquisition): Royal Philips acquired Vesper Medical Inc., which develops minimally invasive peripheral vascular devices. The agreement further expanded Philips' range of diagnostic and therapeutic devices with a line of advanced venous stents for the treatment of deep vein disease.
- August 2020 (Approval): Bentley obtained CE marking for its BeYond venous self-expanding stent system, an open cell Nitinol stent for the treatment of acute and chronic symptomatic femoral or iliac occlusions with a diameter of 10-18 mm and a length of up to 150 mm.
The global Venous Stents Market is segmented as:
- Iliac Vein Stent Technology
- Wallstent Technology
- Acute DVT
- Chronic DVT/PTS
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- North Africa
- South Africa
- Rest of Middle East & Africa
- Latin America
- Rest of Latin America